Also known as: Delta Sleep-Inducing Peptide
A brain peptide discovered in 1977 in sleeping rabbits.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Not fully understood; appears to modulate sleep architecture and stress hormones.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Sleep | C | Limited human data, case series or practitioner reports |
| Stress, anxiety & mood | D | Animal or cell studies only |
At a glance
- Route
- Subcutaneous or IV
- Half-life
- Minutes
Reported dosing
100 to 300 mcg (practitioner reports).
Timing: 1 to 3 hours before bed.
Cycle: Short courses, a few nights to 2 weeks.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Headache, grogginess
Who should avoid it
- Pregnancy
Often combined with
Sometimes with a nighttime GH secretagogue.
Key findings
Small 1980s studies showed mixed results for insomnia and some help with withdrawal symptoms.
2026 update
Jul 2026: the FDA advisory committee voted against allowing compounding (6-7), the only one of 7 peptides rejected.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open DSIP in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.